Prosecution Insights
Last updated: April 18, 2026
Application No. 18/205,621

Method for preparing modified natural oil using organocatalyst supported on polymer and modified natural oil prepared using the same

Final Rejection §102
Filed
Jun 05, 2023
Examiner
CARR, DEBORAH D
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Korea Research Institute Of Chemical Technology
OA Round
2 (Final)
82%
Grant Probability
Favorable
3-4
OA Rounds
2y 7m
To Grant
82%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allow Rate
861 granted / 1055 resolved
+21.6% vs TC avg
Minimal +1% lift
Without
With
+0.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
35 currently pending
Career history
1090
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
31.2%
-8.8% vs TC avg
§102
28.2%
-11.8% vs TC avg
§112
25.7%
-14.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1055 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments, see pages 6-9, filed 25 February 2026, with respect to the rejection of claims 1-3, 5, 9-12 have been fully considered and are persuasive. The rejection has been withdrawn. Applicant's arguments filed 25 February 2026 regarding claim 13 have been fully considered but they are not persuasive. (OLD) Claim Rejections - 35 USC § 102/103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 13 is/are rejected under 35 U.S.C. 102(a)(1)/(a)(2) as being anticipated by Roh et al. (US Pub 2009/0286896, hereafter US’896) Claim 13 recites modified natural oil represented by Chemical Formula 2, prepared by the method of claim 1. US’896 discloses modified natural oils corresponding to the claimed formula, as set forth in the Office action. Claim 13 is in product-by-process form. As previously stated in the Office action, patentability of a product-by-process claim is based on the product itself, not on the recited method of making it, absent a demonstrated structural distinction in the claimed product. Applicant argues that the amended process conditions imply a different monomer/dimer distribution, but claim 13 does not recite any such structural limitation, compositional ratio, or other product-defining characteristic that would distinguish the claimed modified natural oil from the modified natural oils disclosed by US’896. Accordingly, the rejection of claim 13 is maintained. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBORAH D CARR whose telephone number is (571)272-0637. The examiner can normally be reached Monday-Friday (10:30 am -6:30 pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 572-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEBORAH D CARR/Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Jun 05, 2023
Application Filed
Dec 13, 2025
Non-Final Rejection — §102
Feb 25, 2026
Response Filed
Apr 04, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600693
METHOD FOR PRODUCING COMPOUND
2y 5m to grant Granted Apr 14, 2026
Patent 12590055
PROCESS FOR PRODUCING ISOCYANATES
2y 5m to grant Granted Mar 31, 2026
Patent 12582598
A TOPICAL ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING ZILEUTON
2y 5m to grant Granted Mar 24, 2026
Patent 12582627
MCT FORMULATIONS FOR IMPROVING COGNITIVE FUNCTIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12576053
THE NEW USE OF 2-[(3Z)-6-FLUORO-2-METHYL-3-[(4-METHYLSULFINYLPHENYL) METHYLIDENE]INDEN-1 -YL] ACETIC ACID
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
82%
Grant Probability
82%
With Interview (+0.9%)
2y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 1055 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month